Cho Kyung-Hyun, Kim Ji-Eun, Komatsu Tomohiro, Uehara Yoshinari
Raydel Research Institute, Medical Innovation Complex, Daegu 41061, Republic of Korea.
Center for Preventive, Anti-Aging and Regenerative Medicine, Fukuoka University Hospital, 8-19-1 Nanakuma, Johnan-ku, Fukuoka 814-0180, Japan.
Life (Basel). 2023 Jun 4;13(6):1319. doi: 10.3390/life13061319.
Policosanol consumption has been associated with treating blood pressure and dyslipidemia by increasing the level of high-density lipoproteins-cholesterol (HDL-C) and HDL functionality. Although policosanol supplementation also ameliorated liver function in animal models, it has not been reported in a human clinical study, particularly with a 20 mg doage of policosanol. In the current study, twelve-week consumption of Cuban policosanol (Raydel) significantly enhanced the hepatic functions, showing remarkable decreases in hepatic enzymes, blood urea nitrogen, and glycated hemoglobin. From the human trial with Japanese participants, the policosanol group (n = 26, male 13/female 13) showed a remarkable decrease in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) from baseline up to 21% ( = 0.041) and 8.7% ( = 0.017), respectively. In contrast, the placebo group (n = 26, male 13/female 13) showed almost no change or slight elevation. The policosanol group showed a 16% decrease in γ-glutamyl transferase (γ-GTP) at week 12 from the baseline ( = 0.015), while the placebo group showed a 1.2% increase. The policosanol group exhibited significantly lower serum alkaline phosphatase (ALP) levels at week 8 ( = 0.012), week 12 ( = 0.012), and after 4-weeks ( = 0.006) compared to those of the placebo group. After 12 weeks of policosanol consumption, the ferric ion reduction ability and paraoxonase of serum were elevated by 37% ( < 0.001) and 29% ( = 0.004) higher than week 0, while placebo consumption showed no notable changes. Interestingly, glycated hemoglobin (HbA) in serum was lowered significantly in the policosanol group 4 weeks after consumption, which was approximately 2.1% ( = 0.004) lower than the placebo group. In addition, blood urea nitrogen (BUN) and uric acid levels were significantly lower in the policosanol group after 4 weeks: 14% lower ( = 0.002) and 4% lower ( = 0.048) than those of the placebo group, respectively. Repeated measures of ANOVA showed that the policosanol group had remarkable decreases in AST ( = 0.041), ALT ( = 0.008), γ-GTP ( = 0.016), ALP ( = 0.003), HbA ( = 0.010), BUN ( = 0.030), and SBP ( = 0.011) from the changes in the placebo group in point of time and group interaction. In conclusion, 12 weeks of 20 mg consumption of policosanol significantly enhanced hepatic protection by lowering the serum AST, ALT, ALP, and γ-GTP via a decrease in glycated hemoglobin, uric acid, and BUN with an elevation of serum antioxidant abilities. These results suggest that improvements in blood pressure by consumption of 20 mg of policosanol (Raydel) were accompanied by protection of liver function and enhanced kidney function.
服用聚多卡醇已被证明可通过提高高密度脂蛋白胆固醇（HDL-C）水平和HDL功能来治疗血压和血脂异常。虽然在动物模型中补充聚多卡醇也改善了肝功能，但尚未在人体临床研究中得到报道，特别是20毫克剂量的聚多卡醇。在本研究中，连续12周服用古巴聚多卡醇（Raydel）显著增强了肝功能，肝酶、血尿素氮和糖化血红蛋白显著降低。在针对日本参与者的人体试验中，聚多卡醇组（n = 26，男性13名/女性13名）从基线到第21周时，谷丙转氨酶（ALT）和谷草转氨酶（AST）分别显著下降了21%（P = 0.041）和8.7%（P = 0.017）。相比之下，安慰剂组（n = 26，男性13名/女性13名）几乎没有变化或略有升高。聚多卡醇组在第12周时γ-谷氨酰转移酶（γ-GTP）较基线下降了16%（P = 0.015），而安慰剂组上升了1.2%。与安慰剂组相比，聚多卡醇组在第8周（P = 0.012）、第12周（P = 0.012）和4周后（P = 0.006）血清碱性磷酸酶（ALP）水平显著降低。服用聚多卡醇12周后，血清铁离子还原能力和对氧磷酶分别比第0周时升高了37%（P < 0.001）和29%（P = 0.004），而服用安慰剂则无明显变化。有趣的是，服用聚多卡醇4周后，血清糖化血红蛋白（HbA）在聚多卡醇组中显著降低，比安慰剂组低约2.1%（P = 0.004）。此外，4周后聚多卡醇组的血尿素氮（BUN）和尿酸水平显著降低：分别比安慰剂组低14%（P = 0.002）和4%（P = 0.048）。重复测量方差分析显示，聚多卡醇组在AST（P = 0.041）、ALT（P = 0.008）、γ-GTP（P = 0.016）、ALP（P = 0.003）、HbA（P = 0.010）、BUN（P = 0.030）和收缩压（P = 0.011）方面相对于安慰剂组在时间点和组间交互作用上的变化有显著下降。总之，连续12周服用20毫克聚多卡醇通过降低血清AST、ALT、ALP和γ-GTP，同时降低糖化血红蛋白、尿酸和BUN并提高血清抗氧化能力，显著增强了肝脏保护作用。这些结果表明，服用20毫克聚多卡醇（Raydel）改善血压的同时伴随着肝功能的保护和肾功能的增强。
